Andere Kunden interessierten sich auch für
![Kinase-Inhibitoren]( "Kinase-Inhibitoren")
Kinase-Inhibitoren43,90 €![Inibidores da quinase]( "Inibidores da quinase")
Inibidores da quinase29,99 €![Inhibiteurs de kinases]( "Inhibiteurs de kinases")
Inhibiteurs de kinases29,99 €![Inibitori della chinasi]( "Inibitori della chinasi")
Inibitori della chinasi29,99 €![Ingibitory kinaz]( "Ingibitory kinaz")
Ingibitory kinaz29,99 €![Carcinogenesis and Protein Kinase C]( "Carcinogenesis and Protein Kinase C")
Carcinogenesis and Protein Kinase C23,99 €![Design, Synthesis, QSAR Studies of some DPP-IV Inhibitors]( "Design, Synthesis, QSAR Studies of some DPP-IV Inhibitors")
Design, Synthesis, QSAR Studies of some DPP-IV Inhibitors36,99 €
One of the most significant targets of drugs in the 21st century is the family of protein kinase enzymes. There are 62 therapeutic agents authorized by FDA, which target about two dozen distinct proteins. Except for Netarsudil, which is used to treat optical eyes and temsirolimus for renal cell carzinoma, all the FDA-approved medications are orally safe. Key common targets of the medicinal product include BCR-Abl, B-Raf, vascular receptors, VEGFR, and EGFR, as well as ALK. The following are 8 approved drugs of 2020 approved-Tucatinib, Ripretinib, Selumetinib, Capmatinib, Pemigatinib Pralsetinib, Selpercatinib, and Avapritinib. The adenine-binding pocket is occupied by the vast majority of licensed kinase inhibitors. They are classified based on their ability to catalyze the conversion of ATP's terminal phosphate onto substrates containing serine, threonine, or tyrosine residues. Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 72 FDA-approved therapeutic agents that target about two dozen different protein kinases.